Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors - Results from a systematic review and meta-analysis of randomized controlled trials

International Journal of Cardiology

Volumn 189, Issue 1, 2015, Pages 47-55

  Sahebkar, Amirhossein ^a,b   Serban, Corina ^c   Ursoniu, Sorin ^c   Wong, Nathan D ^d   Muntner, Paul ^e   Graham, Ian M ^f   Mikhailidis, Dimitri P ^g   Rizzo, Manfredi ^h   Rysz, Jacek ⁱ   Sperling, Laurence S ^j   Lip, Gregory Y H ^k   Banach, Maciej ⁱ  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ROYAL PERTH HOSPITAL   (Australia)

^c VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY OF PALERMO   (Italy)

ⁱ MEDICAL UNIVERSITY OF LODZ   (Poland)

^j EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF BIRMINGHAM   (United Kingdom)

more..

Author keywords

Antioxidants; C reactive protein; CRP; Inflammation; Resveratrol

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RESVERATROL; TRIACYLGLYCEROL; ANTIOXIDANT; CARDIOTONIC AGENT; STILBENE DERIVATIVE;

ARTICLE; BLOOD LEVEL; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; DATA ANALYSIS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DRUG EFFICACY; HUMAN; META ANALYSIS; MOLECULAR DYNAMICS; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DRUG EFFECTS; FEMALE; MALE; METABOLISM; MORTALITY; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

ANTIOXIDANTS; C-REACTIVE PROTEIN; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STILBENES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84929191468     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.04.008     Document Type: Article

References (67)

1. J.A. Baur, D.A. Sinclair, Therapeutic potential of resveratrol: the in vivo evidence, Nat. Rev. Drug Discov. 5 (2006) 493-506.
2. J. Burns, T. Yokota, H. Ashihara, M.E. Lean, A. Crozier, Plant foods and herbal sources of resveratrol, J. Agric. Food Chem. 50 (2002) 3337-3340.
3. M.M. Lyons, C. Yu, R.B. Toma, S.Y. Cho, W. Reiboldt, J. Lee, et al, Resveratrol in raw and baked blueberries and bilberries, J. Agric. Food Chem. 51 (2003) 5867-5870.
4. S. Renaud, M. de Lorgeril, Wine, alcohol, platelets, and the French paradox for coronary heart disease, Lancet 339 (1992) 1523-1526.
5. S. Pervaiz, Resveratrol: from grapevines to mammalian biology, FASEB J. 17 (2003) 1975-1985.
6. T. Walle, F. Hsieh, M.H. DeLegge, J.E. Oatis Jr., U.K. Walle, High absorption but very low bioavailability of oral resveratrol in humans, Drug Metab. Dispos. 32 (2004) 1377-1382.
7. G.J. Soleas, M. Angelini, L. Grass, E.P. Diamandis, D.M. Goldberg, Absorption of trans-resveratrol in rats, Methods Enzymol. 335 (2001) 145-154.
8. D.M. Goldberg, J. Yan, G.J. Soleas, Absorption of three wine-related polyphenols in three different matrices by healthy subjects, Clin. Biochem. 36 (2003) 79-87.
9. I. Baczko, D. Liknes, W. Yang, K.C. Hamming, G. Searle, K. Jaeger, et al, Characterization of a novel multifunctional resveratrol derivative for the treatment of atrial fibrillation, Br. J. Pharmacol. 171 (2014) 92-106.
10. P. Raj, X.L. Louis, S.J. Thandapilly, A. Movahed, S. Zieroth, T. Netticadan, Potential of resveratrol in the treatment of heart failure, Life Sci. 95 (2014) 63-71.
11. L. Aguirre, M.P. Portillo, E. Hijona, L. Bujanda, Effects of resveratrol and other polyphenols in hepatic steatosis, World J. Gastroenterol. 20 (2014) 7366-7380.
12. J.M. Andrade, A.F. Paraiso, M.V. de Oliveira, A.M. Martins, J.F. Neto, A.L. Guimaraes, et al., Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation, Nutrition 30 (2014) 915-919.
13. V. Ciddi, D. Dodda, Therapeutic potential of resveratrol in diabetic complications: In vitro and in vivo studies, Pharmacol. Rep. 66 (2014) 799-803.
14. Y.K. Bashmakov, S.H. Assaad-Khalil, M. Abou Seif, R. Udumyan, M. Megallaa, K.H. Rohoma, et al, Resveratrol promotes foot ulcer size reduction in type 2 diabetes patients, ISRN Endocrinol. 2014 (2014) 816307.
15. A.A. Bremer, Resveratrol use in metabolic syndrome, Metab. Syndr. Relat. Disord. 10 (2014) 493-495.
16. G.M. Weiner, A.F. Ducruet, Resveratrol and pharmacological potentiation in ischemic stroke, Neurosurgery 74 (2014) N17-N18.
17. L.G. Carter, J.A. D'Orazio, K.J. Pearson, Resveratrol and cancer: focus on in vivo evidence, Endocr. Relat. Cancer 21 (2014) R209-R225.
18. A. Borriello, D. Bencivenga, I. Caldarelli, A. Tramontano, A. Borgia, A.V. Pirozzi, et al, Resveratrol and cancer treatment: is hormesis a yet unsolved matter? Curr. Pharm. Des. 19 (2013) 5384-5393.
19. X. Yang, X. Li, J. Ren, From French paradox to cancer treatment: anti-cancer activities and mechanisms of resveratrol, Anti Cancer Agents Med. Chem. 14 (2014) 806-825.
20. S. Das, D.K. Das, Anti-inflammatory responses of resveratrol, Inflamm. Allergy Drug Targets 6 (2007) 168-173.
21. J. Martinez, J.J. Moreno, Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production, Biochem. Pharmacol. 59 (2000) 865-870.
22. M.J. Zarzuelo, R. Lopez-Sepulveda, M. Sanchez, M. Romero, M. Gomez-Guzman, Z. Ungvary, et al, SIRT1 inhibits NADPH oxidase activation and protects endothelial function in the rat aorta: implications for vascular aging, Biochem. Pharmacol. 85 (2013) 1288-1296.
23. S.E. Chow, Y.C. Hshu, J.S. Wang, J.K. Chen, Resveratrol attenuates oxLDL-stimulated NADPH oxidase activity and protects endothelial cells from oxidative functional damages, J. Appl. Physiol. 102 (2007) 1520-1527.
24. O.H. Kang, H.J. Jang, H.S. Chae, Y.C. Oh, J.G. Choi, Y.S. Lee, et al, Anti-inflammatory mechanisms of resveratrol in activated HMC-1 cells: pivotal roles of NF-kappaB and MAPK, Pharmacol. Res. 59 (2009) 330-337.
25. P.M. Brito, R. Devillard, A. Negre-Salvayre, L.M. Almeida, T.C. Dinis, R. Salvayre, et al, Resveratrol inhibits the mTOR mitogenic signaling evoked by oxidized LDL in smooth muscle cells, Atherosclerosis 205 (2009) 126-134.
26. X.B. Wang, J. Huang, J.G. Zou, E.B. Su, Q.J. Shan, Z.J. Yang, et al, Effects of resveratrol on number and activity of endothelial progenitor cells from human peripheral blood, Clin. Exp. Pharmacol. Physiol. 34 (2007) 1109-1115.
27. F. Bollmann, J. Art, J. Henke, K. Schrick, V. Besche, M. Bros, et al, Resveratrol post-transcriptionally regulates pro-inflammatory gene expression via regulation of KSRP RNA binding activity, Nucleic Acids Res. 42 (2014) 12555-12569.
28. D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, P. Group, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, BMJ 339 (2009) b2535.
29. M.H.L. Borenstein, J. Higgins, et al, Comprehensive Meta-analysis Version 2, Biostat, Englewood NJ, 2005.
30. A. Sahebkar, Does PPARgamma2 gene Pro12Ala polymorphism affect nonalcoholic fatty liver disease risk? Evidence from a meta-analysis, DNA Cell Biol. 32 (2013) 188-198.
31. S. Duval, R. Tweedie, Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis, Biometrics 56 (2000) 455-463.
32. G.C. Bakker, M.J. Van Erk, L. Pellis, S. Wopereis, C.M. Rubingh, N.H. Cnubben, et al, An antiinflammatory dietary mix modulates inflammation and oxidative and metabolic stress in overweight men: a nutrigenomics approach, Am. J. Clin. Nutr. 91 (2010) 1044-1059.
33. Y.K. Bashmakov, S.H. Assaad-Khalil, M. Abou Seif, R. Udumyan, M. Megallaa, K.H. Rohoma, et al, Resveratrol promotes foot ulcer size reduction in type 2 diabetes patients, Int. Sch. Res. Not. 2014 (2014).
34. K. Fujitaka, H. Otani, F. Jo, H. Jo, E. Nomura, M. Iwasaki, et al, Modified resveratrol Longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment, Nutr. Res. 31 (2011) 842-847.
35. K. Magyar, R. Halmosi, A. Palfi, G. Feher, L. Czopf, A. Fulop, et al, Cardioprotection by resveratrol: a human clinical trial in patients with stable coronary artery disease, Clin. Hemorheol. Microcirc. 50 (2012) 179-187.
36. C. Militaru, I. Donoiu, A. Craciun, I.D. Scorei, A.M. Bulearca, R.I. Scorei, Oral resveratrol and calcium fructoborate supplementation in subjects with stable angina pectoris: effects on lipid profiles, inflammation markers, and quality of life, Nutrition 29 (2013) 178-183.
37. M.M. Poulsen, P.F. Vestergaard, B.F. Clasen, Y. Radko, L.P. Christensen, H. Stødkilde-Jørgensen, et al., High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition, Diabetes 62 (2013) 1186-1195.
38. J. Tomé-Carneiro, M. Gonzálvez, M. Larrosa, M.J. Yáñez-Gascón, F.J. García-Almagro, J.A. Ruiz-Ros, et al., One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease, Am. J. Cardiol. 110 (2012) 356-363.
39. A.V. Witte, L. Kerti, D.S. Margulies, A. Flöel, Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults, J. Neurosci. 34 (2014) 7862-7870.
40. L. Wang, M. Martins-Green, Pomegranate and its components as alternative treatment for prostate cancer, Int. J. Mol. Sci. 15 (2014) 14949-14966.
41. J. Yoshino, C. Conte, L. Fontana, B. Mittendorfer, S.-I. Imai, K.B. Schechtman, et al, Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance, Cell Metab. 16 (2012) 658-664.
42. C. Collaboration, Cochrane handbook for systematic reviews of interventions version 5.1. 0. 2011, URL: http://handbookcochrane.org/ [accessed 2014-03-12][WebCite Cache] 2013.
43. H. Ghanim, C.L. Sia, S. Abuaysheh, K. Korzeniewski, P. Patnaik, A. Marumganti, et al, An antiinflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol, J. Clin. Endocrinol. Metab. 95 (2010) E1-E8.
44. H. Ghanim, C.L. Sia, K. Korzeniewski, T. Lohano, S. Abuaysheh, A. Marumganti, et al, A resveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high-carbohydrate meal, J. Clin. Endocrinol. Metab. 96 (2011) 1409-1414.
45. Y. Liu, W. Ma, P. Zhang, S. He, D. Huang, Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials, Clin. Nutr. 34 (2015) 27-34.
46. K. Inanaga, T. Ichiki, H. Matsuura, R. Miyazaki, T. Hashimoto, K. Takeda, et al, Resveratrol attenuates angiotensin II-induced interleukin-6 expression and perivascular fibrosis, Hypertens. Res. 32 (2009) 466-471.
47. R. Miatello, M. Vazquez, N. Renna, M. Cruzado, A.P. Zumino, N. Risler, Chronic administration of resveratrol prevents biochemical cardiovascular changes in fructose-fed rats, Am. J. Hypertens. 18 (2005) 864-870.
48. A. Csiszar, N. Labinskyy, S. Olson, J.T. Pinto, S. Gupte, J.M. Wu, et al, Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats, Hypertension 54 (2009) 668-675.
49. H.Z. Toklu, O. Sehirli, M. Ersahin, S. Suleymanoglu, O. Yiginer, E. Emekli-Alturfan, et al, Resveratrol improves cardiovascular function and reduces oxidative organ damage in the renal, cardiovascular and cerebral tissues of two-kidney, one-clip hypertensive rats, J. Pharm. Pharmacol. 62 (2010) 1784-1793.
50. H.H. Feringa, D.A. Laskey, J.E. Dickson, C.I. Coleman, The effect of grape seed extract on cardiovascular risk markers: a meta-analysis of randomized controlled trials, J. Am. Diet. Assoc. 111 (2011) 1173-1181.
51. K. Liu, R. Zhou, B. Wang, M.T. Mi, Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials, Am. J. Clin. Nutr. 99 (2014) 1510-1519.
52. D.J. Boocock, K.R. Patel, G.E. Faust, D.P. Normolle, T.H. Marczylo, J.A. Crowell, et al, Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography, J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 848 (2007) 182-187.
53. M. Banach, W.S. Aronow, C. Serban, A. Sahabkar, J. Rysz, L. Voroneanu, A. Covic, Lipids, blood pressure and kidney update 2014, Pharmacol. Res. (2015) http://dx.doi.org/10.1016/j.phrs.2015.03.009.
54. E. Wenzel, V. Somoza, Metabolism and bioavailability of trans-resveratrol, Mol. Nutr. Food Res. 49 (2005) 472-481.
55. C. Andreadi, R.G. Britton, K.R. Patel, K. Brown, Resveratrol-sulfates provide an intracellular reservoir for generation ofparent resveratrol, which induces autophagy in cancer cells, Autophagy 10 (2014) 524-525.
56. B. Calamini, K. Ratia, M.G. Malkowski, M. Cuendet, J.M. Pezzuto, B.D. Santarsiero, et al, Pleiotropic mechanisms facilitated by resveratrol and its metabolites, Biochem. J. 429 (2010) 273-282.
57. K. Robinson, C. Mock, D. Liang, Pre-formulation studies of resveratrol, Drug Dev. Ind. Pharm. 1-6 (2014).
58. C.H. Cottart, V. Nivet-Antoine, C. Laguillier-Morizot, J.L. Beaudeux, Resveratrol bioavailability and toxicity in humans, Mol. Nutr. Food Res. 54 (2010) 7-16.
59. R. Corder, W. Mullen, N.Q. Khan, S.C. Marks, E.G. Wood, M.J. Carrier, et al, Oenology: red wine procyanidins and vascular health, Nature 444 (2006) 566.
60. C.H. Cottart, V. Nivet-Antoine, J.L. Beaudeux, Review of recent data on the metabolism, biological effects, and toxicity of resveratrol in humans, Mol. Nutr. Food Res. 58 (2014) 7-21.
61. T. Walle, Bioavailability of resveratrol, Ann. N. Y. Acad. Sci. 1215 (2011) 9-15.
62. C. De Santi, A. Pietrabissa, R. Spisni, F. Mosca, G.M. Pacifici, Sulphation of resveratrol, a natural product present in grapes and wine, in the human liver and duodenum, Xenobiotica 30 (2000) 609-617.
63. J.J. Johnson, M. Nihal, I.A. Siddiqui, C.O. Scarlett, H.H. Bailey, H. Mukhtar, et al, Enhancing the bioavailability of resveratrol by combining it with piperine, Mol. Nutr. Food Res. 55 (2011) 1169-1176.
64. J. Ortuño, M.-I. Covas, M. Farre, M. Pujadas, M. Fito, O. Khymenets, et al, Matrix effects on the bioavailability of resveratrol in humans, Food Chem. 120 (2010) 1123-1130.
65. G. Davidov-Pardo, D.J. McClements, Nutraceutical delivery systems: resveratrol encapsulation in grape seed oil nanoemulsions formed by spontaneous emulsification, Food Chem. 167 (2015) 205-212.
66. Y. Zu, Y. Zhang, W. Wang, X. Zhao, X. Han, K. Wang, et al, Preparation and in vitro/in vivo evaluation of resveratrol-loaded carboxymethyl chitosan nanoparticles, Drug Deliv. (2014) 1-11.
67. H. Yin, J. Si, H. Xu, J. Dong, D. Zheng, X. Lu, et al, Resveratrol-loaded nanoparticles reduce oxidative stress induced by radiation or amyloid-beta in transgenic Caenorhabditis elegans, J. Biomed. Nanotechnol. 10 (2014) 1536-1544.